|
RMD
|
Healthcare |
RBC Capital |
Downgrade
|
Outperform
→
Sector Perform
|
—
|
$30.6B
|
$240.85
|
-1.5%
|
-0.4%
|
-1.2%
|
-0.4%
|
+0.1%
|
-0.2%
|
|
RMD
|
Healthcare |
JP Morgan |
Downgrade
|
Overweight
→
Neutral
|
—
|
$30.6B
|
$240.85
|
-1.5%
|
-0.4%
|
-1.2%
|
-0.4%
|
+0.1%
|
-0.2%
|
|
LEN
|
Consumer Cyclical |
Wedbush |
Downgrade
|
Outperform
→
Neutral
|
—
|
$21.4B
|
$87.76
|
-0.7%
|
+0.6%
|
-0.2%
|
-0.0%
|
-2.1%
|
-0.6%
|
|
AIT
|
Industrials |
Baird |
Downgrade
|
Outperform
→
Neutral
|
—
|
$11.9B
|
$118.89
|
-1.6%
|
-4.6%
|
-0.1%
|
+2.5%
|
-2.2%
|
+1.3%
|
|
CGNX
|
Technology |
JP Morgan |
Downgrade
|
Neutral
→
Underweight
|
—
|
$10.7B
|
$48.48
|
-2.1%
|
-0.5%
|
+0.7%
|
+0.2%
|
-2.7%
|
-0.3%
|
|
RYAN
|
Financial Services |
RBC Capital |
Downgrade
|
Outperform
→
Sector Perform
|
—
|
$9.4B
|
$45.30
|
-2.1%
|
-0.8%
|
+2.9%
|
-1.9%
|
+0.3%
|
+0.6%
|
|
PLXS
|
Technology |
JP Morgan |
Downgrade
|
Neutral
→
Underweight
|
—
|
$6.9B
|
$95.71
|
-1.4%
|
-1.3%
|
+0.4%
|
+1.7%
|
-0.5%
|
+1.5%
|
|
CNTA
|
Healthcare |
Morgan Stanley |
Downgrade
|
Overweight
→
Underweight
|
—
|
$6.1B
|
$4.28
|
-2.6%
|
-0.5%
|
-8.7%
|
+10.0%
|
-0.9%
|
+1.9%
|
|
ELF
|
Consumer Defensive |
TD Cowen |
Downgrade
|
Outperform
→
Market Perform
|
—
|
$3.1B
|
$36.41
|
-1.0%
|
+0.8%
|
+3.4%
|
-0.7%
|
-0.2%
|
+2.2%
|
|
NN
|
Communication Services |
Oppenheimer |
Downgrade
|
Outperform
→
Perform
|
—
|
$3.0B
|
$3.39
|
-3.8%
|
-6.2%
|
-2.5%
|
+2.3%
|
-3.8%
|
+3.9%
|
|
REAL
|
Consumer Cyclical |
TD Cowen |
Downgrade
|
Outperform
→
Market Perform
|
—
|
$2.6B
|
$3.16
|
-1.6%
|
-7.9%
|
-5.5%
|
+22.5%
|
-6.2%
|
-3.5%
|
|
DBD
|
Technology |
JP Morgan |
Downgrade
|
Neutral
→
Underweight
|
—
|
$2.6B
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
MCW
|
Consumer Cyclical |
Morgan Stanley |
Downgrade
|
Overweight
→
Equal Weight
|
—
|
$2.4B
|
$12.00
|
-14.7%
|
-10.1%
|
+6.7%
|
-0.4%
|
-4.0%
|
-1.0%
|
|
ALGT
|
Industrials |
Wolfe Research |
Downgrade
|
Outperform
→
Peer Perform
|
—
|
$1.4B
|
$107.02
|
-0.3%
|
+1.9%
|
+1.2%
|
+1.4%
|
-5.3%
|
-0.4%
|
|
SBH
|
Consumer Cyclical |
TD Cowen |
Downgrade
|
Outperform
→
Market Perform
|
—
|
$1.3B
|
$15.21
|
-4.0%
|
-0.1%
|
+1.3%
|
+1.9%
|
-0.1%
|
+2.0%
|
|
ABSI
|
Healthcare |
JP Morgan |
Downgrade
|
Overweight
→
Underweight
|
—
|
$677M
|
$4.79
|
+7.1%
|
-0.2%
|
+1.0%
|
-5.2%
|
-5.5%
|
-2.3%
|
|
UTZ
|
Consumer Defensive |
Goldman Sachs |
Downgrade
|
Buy
→
Neutral
|
—
|
$655M
|
$17.71
|
-3.4%
|
-1.6%
|
+2.1%
|
-1.8%
|
-0.3%
|
-1.8%
|
|
PD
|
Technology |
Monness, Crespi, Hardt |
Downgrade
|
Buy
→
Neutral
|
—
|
$641M
|
$28.10
|
-3.0%
|
+1.9%
|
+1.8%
|
-3.3%
|
-3.7%
|
+1.2%
|
|
FDMT
|
Healthcare |
SVB Leerink |
Downgrade
|
Outperform
→
Market Perform
|
—
|
$487M
|
$10.40
|
-24.6%
|
-8.3%
|
+0.1%
|
-2.4%
|
-4.0%
|
-2.3%
|
|
LAW
|
Technology |
TD Cowen |
Downgrade
|
Outperform
→
Market Perform
|
—
|
$227M
|
$28.96
|
-43.0%
|
-53.6%
|
+8.6%
|
-0.7%
|
-4.0%
|
+1.6%
|